MX2018003291A - Nuevas estrategias terapeuticas contra el cáncer de sangre. - Google Patents
Nuevas estrategias terapeuticas contra el cáncer de sangre.Info
- Publication number
- MX2018003291A MX2018003291A MX2018003291A MX2018003291A MX2018003291A MX 2018003291 A MX2018003291 A MX 2018003291A MX 2018003291 A MX2018003291 A MX 2018003291A MX 2018003291 A MX2018003291 A MX 2018003291A MX 2018003291 A MX2018003291 A MX 2018003291A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- agent
- blood cancer
- new therapeutic
- therapeutic strategies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a la combinación de por lo menos un agente y una ingesta de calorías reducida para uso en el tratamiento de un cáncer de sangre. En particular, el agente es un inhibidor de CD20, un inhibidor de tirosina quinasa de Bruton, un inhibidor de fosfoinositida 3-quinasa, un inhibidor de histona deacetilasa de clase I y/o clase II, un inhibidor de replicación no taxano o un inhibidor de proteasoma. La combinación es ventajosa porque sensibiliza las células cancerosas a dicho agente mientras protege a las células normales de la toxicidad inducida por dicho agente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562221439P | 2015-09-21 | 2015-09-21 | |
PCT/EP2016/072467 WO2017050849A1 (en) | 2015-09-21 | 2016-09-21 | New therapeutic strategies against blood cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018003291A true MX2018003291A (es) | 2019-02-07 |
Family
ID=56979576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018003291A MX2018003291A (es) | 2015-09-21 | 2016-09-21 | Nuevas estrategias terapeuticas contra el cáncer de sangre. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20200010562A1 (es) |
EP (1) | EP3352793A1 (es) |
JP (1) | JP2018527396A (es) |
KR (1) | KR20180087238A (es) |
CN (1) | CN108601838A (es) |
AU (1) | AU2016328683A1 (es) |
CA (1) | CA2998682A1 (es) |
MX (1) | MX2018003291A (es) |
RU (1) | RU2018114459A (es) |
WO (1) | WO2017050849A1 (es) |
ZA (1) | ZA201802452B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
US20190046513A1 (en) * | 2017-08-10 | 2019-02-14 | Huya Bioscience International, Llc | Combination therapies of hdac inhibitors and tubulin inhibitors |
WO2020206187A1 (en) * | 2019-04-02 | 2020-10-08 | Centagen, Inc | Engineered system of stem cell rejuvenation to treat aging and disease |
IT202000007153A1 (it) * | 2020-04-03 | 2021-10-03 | Ifom Fondazione St Firc Di Oncologia Molecolare | Apporto calorico ridotto e immunoterapia per il trattamento del cancro |
TW202227113A (zh) * | 2020-12-01 | 2022-07-16 | 南加州州立大學 | 模擬禁食飲食提升急性淋巴母細胞白血病模型中的無癌存活 |
WO2023212574A1 (en) * | 2022-04-26 | 2023-11-02 | Olivia Szu Hsieh Lee Nakaya | Compositions and methods for modulating rhythmic activity of pacemaker cardiomyocytes |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007067516A2 (en) * | 2005-12-06 | 2007-06-14 | Duke University | Multiple myeloma |
AU2010310515B2 (en) * | 2009-10-22 | 2016-01-07 | University Of Southern California | Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment |
BR112015029969A2 (pt) * | 2013-05-30 | 2017-07-25 | Infinity Pharmaceuticals Inc | tratamento de câncer usando moduladores de isoformas quinase pi3 |
EP3113776B1 (en) * | 2014-03-06 | 2021-01-13 | University of Southern California | Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues |
-
2016
- 2016-09-21 CN CN201680067777.7A patent/CN108601838A/zh active Pending
- 2016-09-21 US US15/761,287 patent/US20200010562A1/en not_active Abandoned
- 2016-09-21 AU AU2016328683A patent/AU2016328683A1/en not_active Abandoned
- 2016-09-21 CA CA2998682A patent/CA2998682A1/en not_active Abandoned
- 2016-09-21 EP EP16770007.9A patent/EP3352793A1/en active Pending
- 2016-09-21 KR KR1020187011167A patent/KR20180087238A/ko not_active Application Discontinuation
- 2016-09-21 MX MX2018003291A patent/MX2018003291A/es unknown
- 2016-09-21 JP JP2018515027A patent/JP2018527396A/ja active Pending
- 2016-09-21 RU RU2018114459A patent/RU2018114459A/ru not_active Application Discontinuation
- 2016-09-21 WO PCT/EP2016/072467 patent/WO2017050849A1/en active Application Filing
-
2018
- 2018-04-13 ZA ZA2018/02452A patent/ZA201802452B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN108601838A (zh) | 2018-09-28 |
AU2016328683A1 (en) | 2018-05-10 |
RU2018114459A3 (es) | 2020-02-17 |
RU2018114459A (ru) | 2019-10-23 |
WO2017050849A1 (en) | 2017-03-30 |
US20200010562A1 (en) | 2020-01-09 |
ZA201802452B (en) | 2019-07-31 |
EP3352793A1 (en) | 2018-08-01 |
KR20180087238A (ko) | 2018-08-01 |
JP2018527396A (ja) | 2018-09-20 |
CA2998682A1 (en) | 2017-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018003291A (es) | Nuevas estrategias terapeuticas contra el cáncer de sangre. | |
MX2018005600A (es) | Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello. | |
PH12018500040A1 (en) | Indazole and azaindazole compounds as irak-4 inhibitors | |
TW201613644A (en) | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor | |
EA202092154A1 (ru) | Комбинированная терапия | |
MX2018000396A (es) | Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4). | |
PH12015501868A1 (en) | Inhibitors of histone demethylases | |
MY195561A (en) | Indole Carboxamide Compounds useful as Kinase Inhibitors | |
EA201790660A1 (ru) | Ингибитор киназ | |
PH12016502355B1 (en) | Pharmaceutical composition | |
PH12016502256A1 (en) | Medical use | |
BR112015026021A2 (pt) | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer | |
WO2016109217A3 (en) | Btk inhibitors | |
BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
PH12016502353A1 (en) | Pharmaceutical composition | |
EA200802223A1 (ru) | 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90 | |
TW201625535A (en) | Inhibitors of histone demethylases | |
TW201613577A (en) | Pharmaceutical combinations | |
MX2016014365A (es) | Terapias combinadas dirigidas a mitocondrias para la terapia contra cancer. | |
WO2018208793A8 (en) | S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY | |
NZ726695A (en) | Gls1 inhibitors for treating disease | |
WO2016004413A3 (en) | Gls1 inhibitors for treating disease | |
EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
BR112019018028A2 (pt) | Composto, combinação, e. uso de um composto ou um sal farmaceuticamente aceitável do mesmo | |
JOP20190178A1 (ar) | تركيبة صيدلانية تتضمن مشتق أوكسازين واستخدامها في علاج أو الوقاية من مرض الزهايمر |